Funding

NIH/NINDS RO1NS122834-02S1 : Role of Brainstem Cardiorespiratory Neurons in SUDEP. 2/2022 – 12/2026.
NIH/NINDS RO1NS120702:– Role of CACHD1 in Modulating Neuronal Hyperexcitability in Epilepsy. 7/2021 – 6/2026.
NIH/NINDS RO1NS103090: Pathogenesis of Epilepsy in a SCN8A Human Mutation Mouse Model.  1/2018-12/2022.
Biomedical Innovations Fund (UVA): Preclinical Testing of Nav1.6 selective Sodium Channel Antagonists for the Suppression of Epileptic Seizures and the Prevention of SUDEP. Feb 2016 – Jan 2021.
Virginia Brain Institute Grant . Remote Suppression of Epileptic Seizures. 2/1/2017- 1/31/2018.
NIH/NINDS R21NS080061: Na Channel Beta 4 as a Gene Therapy Target for Epilepsy. 7/2012-6/2014
NIH/NINDS RO1NS075157: Sodium Channels and Neuronal Excitability in Chronic Limbic Epilepsy. 2/2012-1/2017
NIH/NINDS R21NS061069: Development of Novel Antiepileptic Drugs. 2/2009-1/2011
Epilepsy Foundation of America: Alterations in Sodium Channels in Epileptogenesis. Jan 2011 – Dec /2011
Alzheimer’s and Related Diseases: Cleavage of sodium channel β3 subunit by BACE1 and γ-secretase modulates sodium channel activity in brain neurons. 8/2008-7/2009
American Heart Association Virginia Affiliate: β- Subunit Regulation of the Cardiac Sodium Channel. 7/2002-6/2004

PHARMACEUTICAL GRANTS:
Stoke Therapeutics: Evaluation of Stoke Therapeutics SCN1A ASO on seizures in Scn1a+/- DS mice. April 2019 – April 2020.
Praxis Precision Medicine LLC.  Evaluation of PRAX-562 on seizure activity in N1768D heterozygous (D/+) mice. Oct 2018 – Jan 2021.
Xenon Pharmaceuticals: Testing Xenon Compound on Seizure Frequency in a Human Mutation Mouse Model of Epilepsy.      Mar 2016 – July 2016.
Pfizer GRD: Testing Nav1.7 Selective Compounds on Lamina II Dorsal Horn Projection Neurons in Adult Rat Spinal Cord. Sep 2011 – Dec 2015: